Patents Represented by Attorney, Agent or Law Firm Robert L Buchanan
-
Patent number: 6794499Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes will single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: September 11, 1998Date of Patent: September 21, 2004Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 6770620Abstract: The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.Type: GrantFiled: September 17, 2001Date of Patent: August 3, 2004Assignee: Sanos Bioscience A/SInventor: Dennis Bang Henriksen
-
Patent number: 6723838Abstract: The present invention features molecules that relate to SYNGAP (Synaptic GTPase Activating Protein), an excitatory synapse protein that has been found to bind synaptic proteins and modulate signal transduction. In one aspect, the invention provides isolated polynucleotides that encode SYNGAP or fragments or derivatives thereof. Further provided are SYNGAP or SYNGAP-related polypeptides encoded by the polynucleotides. In another aspect, the invention provides immunological molocules that are capable of binding the polypetides. Additionally provided are methods for using the molocules of this invention, e.g., to treat or prevent a disorder mediated by SYNGAP. The invention also provides screening assays for detecting compounds useful in the diagnosis or treatment of disorders impacted by SYNGAP.Type: GrantFiled: April 19, 1999Date of Patent: April 20, 2004Assignee: Johns Hopkins UniversityInventors: Richard L. Huganir, Jee Hae Kim
-
Patent number: 6676937Abstract: The present invention generally provides methods for modulating formation of new blood vessels. In one embodiment, the methods include administering to a mammal an effective amount of granulocyte macrophage-colony stimulating factor (GM-CSF) sufficient to form the new blood vessels. Additionally provided are methods for preventing or reducing the severity of blood vessel damage in a mammal which methods preferably include administering to the mammal an effective amount of GM-CSF. Provided also as part of this invention are pharmaceutical products and kits for inducing formation of new blood vessels in the mammal.Type: GrantFiled: March 9, 1999Date of Patent: January 13, 2004Assignee: Caritas St. Elizabeth's Medical Center of Boston Inc.Inventors: Jeffrey M. Isner, Takayuki Asahara
-
Patent number: 6670461Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: May 9, 2001Date of Patent: December 30, 2003Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 6645501Abstract: The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.Type: GrantFiled: February 1, 2001Date of Patent: November 11, 2003Assignee: Washington UniversityInventor: Steven F. Dowdy
-
Patent number: 6593453Abstract: Novel activated peptides and conjugates thereof, useful in diagnostic assays and therapeutics, and processes for the preparation thereof are disclosed.Type: GrantFiled: September 2, 1999Date of Patent: July 15, 2003Assignee: Dade Behring Marburg GmbHInventors: Michael E. Annunziato, Paul S. Palumbo
-
Patent number: 6590090Abstract: This invention relates to a Fas ligand-like protein having an apotosis-inducing actibvity, etc. or its salt, a partial peptide of the protein or its salt; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein, a pharmaceutical composition comprising the protein, the partial peptide or its salt; and an antibody to the protein or the partial peptide. The protein, the partial peptide or its salt, and the DNA are useful as a prophylactic or therapeutic agent for cancer, viral infection, Helicobacter pylori infection, invasive staphylococcia, hepatitis, nephritis, bone disease, atherosclerosis or pain. The antibody can be used in assay of the protein, the partial peptide or its salt. The protein, the partial peptide or its salt is useful as a reagent for the screening for candidate medical compounds.Type: GrantFiled: August 31, 2000Date of Patent: July 8, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Kazunori Nishi, Yukiko Hikichi, Yasushi Shintani
-
Patent number: 6566140Abstract: The present invention provides methods for inhibiting blood clotting. In general, the methods include adding corn trypsin inhibitor (CTI) to blood or a blood product in an amount sufficient to inhibit the clotting. The CTI can be used alone or in combination with other anti-coagulants. In one aspect, the invention features plasma clotting assays featuring substantially prolonged clotting times. Clotting assays using whole or minimally altered blood are also provided. Further provided are methods for storing blood or blood products at low temperature with the CTI.Type: GrantFiled: April 27, 2001Date of Patent: May 20, 2003Assignee: University of Vermont and State Agriculture CollegeInventors: Kenneth G. Mann, Mathew D. Rand, Kevin M. Cawthern
-
Patent number: 6555319Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.Type: GrantFiled: April 16, 1999Date of Patent: April 29, 2003Assignee: Sunol Molecular CorporationInventors: Hing C. Wong, Jin-An Jiao, Esperanza Liliana Nieves, Lawrence Luepschen
-
Patent number: 6534633Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.Type: GrantFiled: October 21, 1999Date of Patent: March 18, 2003Assignee: Altor Bioscience CorporationInventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong
-
Patent number: 6528486Abstract: The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.Type: GrantFiled: July 12, 2000Date of Patent: March 4, 2003Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Jens Damsgaard Mikkelsen, Søren Neve
-
Patent number: 6511979Abstract: The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDPGal:GlcCer&bgr;1→4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.Type: GrantFiled: July 22, 1999Date of Patent: January 28, 2003Assignee: Johns Hopkins UniversityInventor: Subroto Chatterjee
-
Patent number: 6492324Abstract: This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.Type: GrantFiled: February 22, 1999Date of Patent: December 10, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Kazuhiko Tatemoto, Masaki Hosoya, Yugo Habata, Ryo Fujii, Chieko Kitada
-
Patent number: 6440167Abstract: The present invention relates to a collagen material comprising a laminate in which a collagen ultra-fine fibrous non-woven fabric-like multi-layer structure is sandwiched between non-fibrous collagen layers, a thread-like material containing said collagen material, their production processes, and a medical material containing said collagen material, and particularly a medical alternative membrane comprised of said medical material.Type: GrantFiled: January 16, 2001Date of Patent: August 27, 2002Assignees: Tapic International Co., Ltd.Inventor: Yasuhiko Shimizu
-
Patent number: 6403381Abstract: The present invention provides methods for inhibiting blood clotting. In general, the methods include adding corn trypsin inhibitor (CTI) to blood or a blood product in an amount sufficient to inhibit the clotting. The CTI can be used alone or in combination with other anti-coagulants. In one aspect, the invention features plasma clotting assays featuring substantially prolonged clotting times. Clotting assays using whole or minimally altered blood are also provided. Further provided are methods for storing blood or blood products at low temperature with the CTI.Type: GrantFiled: June 8, 1999Date of Patent: June 11, 2002Assignee: University of Vermont and State Agriculture CollegeInventors: Kenneth G. Mann, Mathew D. Rand, Kevin M. Cawthern
-
Patent number: 6365364Abstract: The present invention features isolated angiogenesis inhibitors having a molecular weight of between about 40 kDa to 50 kDa and having an amino acid sequence substantially similar to that of the amino acid sequence shown in SEQ ID NO. 2 or SEQ ID NO. 3. Further provided are methods of making and using the angiogenesis inhibitors, e.g., to inhibit vascularization or to block osteonectin and plasminogen interaction.Type: GrantFiled: August 19, 1999Date of Patent: April 2, 2002Assignee: University of Vermont and State Agriculture CollegeInventors: Kenneth G. Mann, Nancy Swords Jenny
-
Patent number: 6309645Abstract: The present invention relates to novel complexes of major histocomability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to loaded MHC complexes that include at least one MHC molecule with a peptide-binding groove and a presenting peptide non-covalently linked to the MHC protein. In another aspect, the invention features single chain MHC class II peptide fusion complexes with a presenting peptide covalently linked to the peptide binding grove of the complex. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.Type: GrantFiled: April 28, 1998Date of Patent: October 30, 2001Assignee: Sunol Molecular CorporationInventors: Peter R. Rhode, Jin-An Jiao, Martin Burkhardt, Hing C. Wong
-
Patent number: 6306605Abstract: Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.Type: GrantFiled: February 1, 2000Date of Patent: October 23, 2001Assignee: Sunol Molecular CorporationInventors: Jorge L. Acevedo, Peter R. Rhode
-
Patent number: D495806Type: GrantFiled: February 7, 2003Date of Patent: September 7, 2004Assignee: Exiqon A/SInventor: Mikkel Nørholm